Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate
(2007) Journal of Bone and Mineral Research — Vol. 22, n° 1, p. 142-148 (2007)
Files
37877.pdf
Open Access - Adobe PDF
- 1.67 MB
Details
- Authors
- Abstract
- A single 5-mg infusion of zoledronic acid restores biochemical markers of bone turnover into the reference range in the majority of patients with Paget's disease and maintains biochemical remission for at least 2 years. This effect is largely independent of pretreatment disease activity and prior bisphosphonate therapy.
- Affiliations
Citations
Hosking, D., Lyles, K., Brown, J. P., Fraser, W. D., Miller, P., Curiel, M. D., Devogelaer, J.-P., Hooper, M., Su, G., Zelenakas, K., Pak, J., Fashola, T., Saidi, Y., Eriksen, E. F., & Reid, I. R. (2007). Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. Journal of Bone and Mineral Research, 22(1), 142-148. https://doi.org/10.1359/JBMR.061001 (Original work published 2007)